Actavis, Inc. News Headlines

ACT 
$263.01
*  
2.38
0.9%
Get ACT Alerts
*Delayed - data as of Dec. 22, 2014 10:31 ET  -  Find a broker to begin trading ACT now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    ACT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
It's Not the Zombie Apocalypse, but Killer Superbugs Could Be on the Way
12/14/2014 7:44:04 AM - Motley Fool


What Investors Can Learn From The Portfolios Of Fund Managers
12/14/2014 5:47:00 AM - Seeking Alpha


Chilton opens new position in Wynn Resorts
12/12/2014 4:00:00 PM - Market Realist


Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
12/12/2014 3:20:00 PM - Zacks.com


Chilton starts new position in Medtronic
12/12/2014 12:00:00 PM - Market Realist


Chilton initiates new position in Actavis
12/12/2014 8:00:00 AM - Market Realist


Actavis Ordered By Court To Keep Selling Immediate-release Alzheimer''s Drug
12/11/2014 11:27:00 PM - RTT News


Chilton opens new position in Wynn Resorts
12/11/2014 8:22:00 PM - Market Realist


Highlights of Chilton Investment Company’s 3Q14 13F
12/11/2014 8:12:00 PM - Market Realist


bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog
12/11/2014 4:45:00 PM - Zacks.com


Mylan Among First to Launch Generic Celebrex - Analyst Blog
12/11/2014 4:22:00 PM - Zacks.com


Drivers Of The Rally: Megamergers And Monetary Stimuli
12/10/2014 5:33:00 PM - Market Realist


Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
12/10/2014 3:30:00 PM - Zacks.com


Actavis Unveils Generic Version Of Celebrex - Quick Facts
12/10/2014 9:35:00 AM - RTT News


Google, Microsoft Dominate Mutual Funds, Apple Still Most Popular In Hedge Funds: Citigroup
12/8/2014 8:13:00 PM - Seeking Alpha


Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog
12/8/2014 6:30:00 PM - Zacks.com


Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
12/8/2014 5:10:00 PM - Zacks.com


Is It Time to Buy This Growth Stock?
12/8/2014 9:43:02 AM - Motley Fool


Why 2014 Is the Biggest Year for Deals Since the Financial Crisis
12/8/2014 6:10:00 AM - TheStreet


The 3 Most Memorable Moments in Healthcare This Year
12/7/2014 3:02:02 PM - Motley Fool


Actavis: FDA Committee Recommends Approval Of Antibiotic Ceftazidime-avibactam
12/5/2014 4:51:00 PM - RTT News


Consumer Health Spending a Welcome Wrinkle for Allergan-Actavis Deal
12/4/2014 10:24:02 AM - Motley Fool


Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog
12/3/2014 4:30:00 PM - Zacks.com


Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
12/3/2014 3:41:00 PM - Seeking Alpha


5 Stocks Hedge Funds Love: Alibaba, MIcrosoft and More
12/3/2014 10:35:00 AM - TheStreet